Skip to main content
OpenTrials
Completed

NCT Number: NCT03655730

Efficacity of Psychological Intervention on Reducing the Suicidal Ideations, Depression Level and Improving Reinsertion

Suicide is the third leading cause of death in adolescents and young adults in the United States and the second leading cause in European countries.

Depressive disorders are consistently the most prevalent psychiatric disorder among adolescents who attempt suicide with a prevalence ranging from 49% to 64%. Depression in adolescent and young adults is a multifactorial phenomenon, as is the risk of suicidal attempt. To address such problems, effective and accessible treatment is needed, as recommended by the French Health Authority (HAS).

Our primary objective is to demonstrate that a weekly psychotherapeutic intervention reduces the depression level.

The primary assessment criterion is the variation of the clinician Adolescent Depression Rating Scale (ADRSc) from randomisation to month 6.

The study also aims comparing in the 2 randomised groups

* ADRS depression global score (clinician and subject) at 0, 3, 9 and 12 months * Number of suicidal attempts and self-harm attempts at 6 and 12 months * Number of drop-out at 6 and 12 months * Beck's Hopelessness Scale at 0, 3, 6, 9 and 12 months * Global score on the GHQ-28 and scores on the 4 subscales (Somatization, Anxiety and Insomnia, Social dysfunction, Depressive mood) at 0, 3, 6, 9 and 12 months. * Working AIliance Inventory (WAI) score at 0, 3, 6, 9 and 12 months

Completed

Looking for future studies?

Notify Me

Key information

Age range

16 year–25 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Bichat hospital

Paris, 75018, France

About this study

Suicide is the third leading cause of death in adolescents and young adults in the United States and the second leading cause in European countries. In France, recent epidemiological data showed that the suicide rate in adolescents aged 15 to 19 is 4.1/100 000 inhabitants. Prevalence of suicidal ideations ranges from 15 to 25% in the general population and lifetime estimates of suicide attempts among adolescents range from 1.3 to 3.8% in males and from 1.5 to 10.1% in females. Reducing suicide and suicide attempts is therefore a key public health target.

Depressive disorders are consistently the most prevalent psychiatric disorder among adolescents who attempt suicide with a prevalence ranging from 49% to 64%. Depression in adolescent and young adults is a multifactorial phenomenon, as is the risk of suicidal attempt.

Being in a situation of failure at school or not having a clear training or work project clearly increases the risk for depression. Some studies have targeted potential high school drop outs as a target for prevention of suicidality.

To address such problems, effective and accessible treatment is needed, as recommended by the French Health Authority (HAS). However, only few studies assess, through a randomized protocol, efficacity and feasibility of psychotherapeutic treatment in psychiatry in general and particularly in this population, although individual psychotherapy is highly recommended in clinical practice for depressed adolescents and young adults.

Our primary objective is to demonstrate that a weekly psychotherapeutic intervention reduces the depression level.

The primary assessment criterion is the variation of the clinician Adolescent Depression Rating Scale (ADRSc) from randomisation to month 6.

Others objectives are the following :

To compare in the 2 randomised groups

  • ADRS depression global score (clinician and subject) at 0, 3, 9 and 12 months
  • Number of suicidal attempts and self-harm attempts at 6 and 12 months
  • Number of drop-out at 6 and 12 months
  • Beck's Hopelessness Scale at 0, 3, 6, 9 and 12 months
  • Global score on the GHQ-28 and scores on the 4 subscales (Somatization, Anxiety and Insomnia, Social dysfunction, Depressive mood) at 0, 3, 6, 9 and 12 months.
  • Working AIliance Inventory (WAI) score at 0, 3, 6, 9 and 12 months

To describe, in the whole sample (randomised and not randomised),

  • the baseline level of abuse during childhood with the CTQ. The effectiveness of reinsertion activities (jobs, diploma, attendance to the Mission Locale) at 0, 3, 6, 9 and 12 months

To evaluate the sensitivity to change of the French version of the ADRSc.

330 subjects wil be included to have 132 randomized subjects into two arms: sustained psychotherapeutic intervention or usual care.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Be followed in one of the five participating centres of Mission Locale in Paris,
  • Be between 16 (inclusive) and 25 (inclusive) years old at the date of inclusion,
  • Agrees to participate in the research and, in the case of a minor, the legal representant agrees with the subject's participation in research.
  • Have a Social Security number
  • Be fluent in French
  • With signed informed consent

Exclusion criteria

  • Be already followed in a mental health/addiction service, attending to a private or public psychiatric service, or abusing drugs.

Randomisation criteria :

Included subjects will be randomised if at least one of the following conditions is met: baseline ADRSc score greater or equal than 8 or abuse and/or deprivation according to the Childhood Trauma Questionnaire (CTQ, short version):

  • score greater or equal than 11 relative to physical abuse
  • score greater or equal than 16 relative to emotional abuse
  • score greater or equal than 14 relative to physical deprivation
  • score greater or equal than 11 relative to sexual abuse).

Treatment and study plan

weekly psychotherapeutic individual sessions

Other

weekly psychotherapeutic individual sessions following the IPT method during one year

Usual Care

Other

the standard follow-up provided by the Mission Locale, including periodic meetings with a referee

Primary outcomes

  1. Depression level

    Time frame: 6 months

    Defined as the difference of ADRS clinician score (cf. Appendix 18.2.1) between inclusion and 6 month.

Secondary outcomes

  1. depression assessed at 0, 3, 9 and 12 months

    Time frame: at 0, 3, 9 and 12 months

    The ADRSc (clinician) questionnaire will be filled out by the assessor at 0, 3 and 9 and 12 months during follow-up visits

  2. suicidal attempts and self-harm attempts

    Time frame: at 6 and 12 months

    The number of suicidal attempts and self-harm attempts, at 6 and 12 months

  3. drop out

    Time frame: at baseline, 6 and 12 months

    The number of drop outs at baseline, 6 and 12 months

  4. time of the hopelessness

    Time frame: t 0, 3, 6, 9 and 12 months

    The evolution on time of the hopelessness, assessed at 0, 3, 6, 9 and 12 months

  5. global score on the GHQ28

    Time frame: at 0, 3, 6, 9 and 12 months

    • The evolution on time of the global score on the GHQ28 and on its 4 subscales (Somatization, Anxiety and Insomnia, Social dysfunction, Depressive mood), assessed at 0, 3, 6, 9 and 12 months
  6. working aIliance

    Time frame: at 0, 3, 6, 9 and 12 months

    The evolution on time of the working aIliance at 0, 3, 6, 9 and 12 months

Sponsors and collaborators

Lead sponsor

Assistance Publique - Hôpitaux de Paris

Other

Registry information

Official study title

Efficacity of a Sustained Weekly Psychological Intervention for Adolescents and Young Adults Attending to Local Missions for Reinsertion, on Reducing the Suicidal Ideations, Depression Level and Improving Reinsertion Compared to Usual Care

Acronym: MLADO

Important dates

Study start
2018
Primary completion
2021
Study completion
2021
First posted
Aug 31, 2018
Registry last updated
Jun 28, 2021

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.